title: Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy.
abstract: The use of replication-competent adenoviruses (Ads) for cancer therapy is receiving widespread attention, especially for the treatment of tumors refractory to current treatments such as glioblastoma. AdDelta24, which carries a 24-bp deletion in E1A and replicates in cells with a retinoblastoma-defective pathway, produced a strong antitumor effect in glioma. To improve infection efficiency of primary glioma cells, which express low levels of coxsackie adenovirus receptor (CAR), the tropism of AdDelta24 was expanded toward alphav integrins by insertion of an Arg-Gly-Asp (RGD) motif into the fiber knob (Ad5-Delta24RGD). We show that Ad5-Delta24RGD had a stronger oncolytic effect than the non-RGD-expressing variant on a broad panel of primary glioma cells, in particular on those with low CAR expression. The effects of Ad5-Delta24RGD were also assessed on a panel of primary organotypic glioma spheroids. In all cases, Ad5-Delta24RGD strongly decreased the viability of these small tumor nodules in vitro. In s.c. glioblastoma xenografts expressing low levels of CAR, five intratumoral injections of 1 x 10(7) plaque-forming units Ad5-Delta24RGD resulted in complete tumor regression in 9 of 10 mice and long-term survival in all treated mice. Preclinical evaluations and clinical trials of replication-competent Ad have shown more promising results when combined with conventional therapeutics. Therefore, we assessed the effects of Ad5-Delta24RGD in combination with radiotherapy. Low-dose irradiation before Ad5-Delta24RGD infection decreased viability of glioma cells more effectively than Ad5-Delta24RGD alone with effects ranging from additive to supra-additive. In addition, combination treatment with Ad5-Delta24RGD and irradiation was studied in glioma xenografts. Five injections of 1 x 10(6) plaque-forming units Ad5-Delta24RGD induced significant tumor growth delay of >119 days compared with untreated controls and led to long-term survival in 6 of 9 mice. When viral treatment was combined with irradiation, tumor regression occurred in all mice resulting in long-term survival without evidence of tumor regrowth in 10 of 10 cases. This study thus provides evidence that Ad5-Delta24RGD has strong antitumor activity in malignant glioma, which can be additionally enhanced by irradiation such that the same therapeutic effect is achieved when a 10-fold lower viral dose is applied. These results support further development of Ad5-Delta24RGD in combination with radiation therapy for treatment of these highly malignant tumors.
authors.affiliation: Department of Neurosurgery, VU University Medical Center, 1007 MB Amsterdam, the Netherlands. M.Lamfers@vumc.nl
authors.forename: Martine L M
authors.initials: ML
authors.lastname: Lamfers
authors.forename: Jacques
authors.initials: J
authors.lastname: Grill
authors.forename: Clemens M F
authors.initials: CM
authors.lastname: Dirven
authors.forename: Victor W
authors.initials: VW
authors.lastname: Van Beusechem
authors.forename: Birgit
authors.initials: B
authors.lastname: Geoerger
authors.forename: Jaap
authors.initials: J
authors.lastname: Van Den Berg
authors.forename: Ramon
authors.initials: R
authors.lastname: Alemany
authors.forename: Juan
authors.initials: J
authors.lastname: Fueyo
authors.forename: David T
authors.initials: DT
authors.lastname: Curiel
authors.forename: Gilles
authors.initials: G
authors.lastname: Vassal
authors.forename: Herbert M
authors.initials: HM
authors.lastname: Pinedo
authors.forename: W Peter
authors.initials: WP
authors.lastname: Vandertop
authors.forename: Winald R
authors.initials: WR
authors.lastname: Gerritsen
mesh_terms: D000256:Adenoviridae / Q000235:genetics / Q000378:metabolism / Q000502:physiology*; D000328:Adult; D000368:Aged; D000818:Animals; D001254:Astrocytoma / Q000378:metabolism / Q000532:radiotherapy / Q000628:therapy* / Q000821:virology; D001932:Brain Neoplasms / Q000378:metabolism / Q000532:radiotherapy / Q000628:therapy* / Q000821:virology; D003131:Combined Modality Therapy; D062727:Coxsackie and Adenovirus Receptor-Like Membrane Protein; D005260:Female; D005909:Glioblastoma / Q000378:metabolism / Q000532:radiotherapy / Q000628:therapy* / Q000821:virology; D006801:Humans; D039302:Integrin alphaVbeta3 / Q000096:biosynthesis / Q000378:metabolism; D016023:Integrins / Q000096:biosynthesis / Q000378:metabolism; D008297:Male; D051379:Mice; D008819:Mice, Nude; D008875:Middle Aged; D009842:Oligopeptides / Q000235:genetics / Q000378:metabolism*; D011991:Receptors, Virus / Q000096:biosynthesis / Q000378:metabolism; D019030:Receptors, Vitronectin / Q000096:biosynthesis / Q000378:metabolism; D018874:Spheroids, Cellular; D014407:Tumor Cells, Cultured; D014779:Virus Replication; D023041:Xenograft Model Antitumor Assays
chemical_list: C568771:CLMP protein, human; C568772:CLMP protein, mouse; D062727:Coxsackie and Adenovirus Receptor-Like Membrane Protein; D039302:Integrin alphaVbeta3; D016023:Integrins; D009842:Oligopeptides; D011991:Receptors, Virus; D019030:Receptors, Vitronectin; C064660:integrin alphaVbeta5; C047981:arginyl-glycyl-aspartic acid